Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Gilead 4Q Results | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Gilead 4Q Results

Product sales were down due to lower Veklury and HIV sales, partially offset by higher Oncology sales.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead
4Q Revenues: $7.1 billion (-4%)
4Q Earnings: $1.4 billion (-13%)
FY Revenues: $27.1 billion (-1%)
FY Earnings: $5.6 billion (+23%)
Comments: Product sales were down in the quarter due to lower Veklury (remdesivir) and HIV sales, partially offset by higher Oncology sales. Veklury sales were down 28% to $720 million. Descovy sales were down 5% to $509 million in the quarter. Biktarvy sales were up 7% in the quarter to $3.1 billion. Liver Disease portfolio sales were flat at $691 million in the quarter. Cell Therapy product sales increased 11% to $466 million in the quarter. Yescarta sales increased 9% to $368 million. Tecartus sales increased 19% to $98 million. Trodelvy sales increased 53% to $299 million. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters